Marc

Marc Therapeutics is a pre-clinical stage biotechnology company focused on developing first-in-class inhibitors of executioner caspases to prevent programmed cell death. The company's lead programs target Caspase-3 and Caspase-7, which are central mediators of apoptosis in various acute and chronic degenerative conditions. By inhibiting these enzymes, Marc Therapeutics aims to protect tissues from damage in indications such as acute kidney injury and ischemia-reperfusion injury. Their approach seeks to provide therapeutic intervention at the final stage of the cell death pathway, potentially offering superior efficacy in preserving organ function compared to upstream inhibitors.